A Phase II study published in JAMA Dermatology showed that the TYK2 inhibitor soficitinib is effective and safe for patients with moderate-to-severe atopic dermatitis (AD). The study included 75 participants who received either soficitinib or placebo, with soficitinib showing significant improvement in Eczema Area and Severity Index (EASI) scores. Soficitinib also provided rapid relief of itching and improved quality of life. The drug had a good safety profile, with mild or moderate side effects. A Phase III trial for soficitinib in AD is underway, with promising results so far.

Soficitinib, a TYK2 inhibitor, has shown effectiveness in treating atopic dermatitis and other autoimmune disorders. In a Phase II study, soficitinib demonstrated significant improvement in EASI scores and quality of life for patients with AD. The drug also had a favorable safety profile with mild or moderate side effects. A Phase III trial for soficitinib in AD is ongoing, with positive results from the Phase II study. This promising treatment could benefit patients with moderate-to-severe atopic dermatitis.

Read more at GlobeNewswire: Study Results of Novel TYK2 Inhibitor Soficitinib in